X4 Pharmaceuticals
NASDAQ: XFORBoston, US · Founded 2010 · Delaware corporation · 2 known investors
Founders & leadership
MD
Mary DiBiaseExecutive
CA
Christophe Arbet-EngelsExecutive
DK
David KirskeExecutive
JV
John VolponeExecutive
MB
Mark BaldryExecutive
AC
Adam CraigExecutive
TU
Tillman U GerngrossNamed on SEC filing
EN
Eszter NagyNamed on SEC filing
Board
FD
Francoise De CraeckerBoard director
CG
Carl GordonBoard director
MR
Michael RossBoard director
CN
Investors · 2
Reported raises · per SEC filings
Form D private placements$310.3M disclosed across 8 rounds · 2013–2025
▶$85MraisedAug 2025 · 18 investors · BiotechnologyRule 506(b)
▶$85MraisedAug 2025 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mary DiBiaseExecutive Officer
- Murray W. StewartDirector
- Christophe Arbet-EngelsExecutive Officer
- David KirskeExecutive Officer
- Michael S. WyzgaDirector
- John VolponeExecutive Officer
- Mark BaldryExecutive Officer
- Francoise De CraeckerDirector
- Gary J. BridgerDirector
- Adam CraigExecutive Officer, Director
- Offering amount
- $85M
- Amount sold
- $85M
- Sales commissions
- $3.3M
- Placement agents
- STIFEL, NICOLAUS & COMPANY, INCORPORATED
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$65MraisedJun 2023 · 22 investors · BiotechnologyRule 506(b)
▶$65MraisedJun 2023 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David McGirrDirector
- Francoise de CraeckerDirector
- Adam MostafaExecutive Officer
- Michael WyzgaDirector
- Arthur TaverasExecutive Officer
- Mary DiBiaseExecutive Officer
- Murray StewartExecutive Officer, Director
- William AliskiDirector
- Alison LawtonDirector
- Gary BridgerDirector
- Mark BaldryExecutive Officer
- Paula RaganExecutive Officer, Director
- Offering amount
- $65M
- Amount sold
- $65M
- Sales commissions
- $4M
- Placement agents
- Cantor Fitzgerald & Co., Piper Sandler & Co., Stifel, Nicolaus & Company, Inc.
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$55.7MraisedJul 2022 · 23 investors · BiotechnologyRule 506(b)
▶$55.7MraisedJul 2022 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adam S. MostafaExecutive Officer
- Arthur TaverasExecutive Officer
- David McGirrDirector
- Francoise de CraeckerDirector
- Michael S. WyzgaDirector
- Paula RaganExecutive Officer, Director
- Diego CadavidExecutive Officer
- Mary DiBiaseExecutive Officer
- Murray W. StewartDirector
- Gary J. BridgerDirector
- Derek MeisnerExecutive Officer
- Alison LawtonDirector
- William E. AliskiDirector
- Offering amount
- $111.5M
- Amount sold
- $55.7M
- Sales commissions
- $2.8M
- Placement agents
- Stifel, Nicolaus & Company, Inc.
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedDec 2017 · 1 investors · BiotechnologyRule 506(c)
▶$20MraisedDec 2017 · 1 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Amy SchulmanDirector
- Michael RossDirector
- Claudio NessiDirector
- Carl GordonDirector
- David MantusExecutive Officer
- Chris StevensExecutive Officer
- William ClarkDirector
- David McGirrDirector
- Eszter NagyExecutive Officer
- Michael GrayExecutive Officer
- Tillman U. GerngrossDirector
- Terrance McGuireDirector
- Rene RussoExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $20M
- Sales commissions
- $1.4M
- Placement agents
- Citigroup Global Markets Inc., Cowen and Company, LLC, Piper Jaffray & Co.
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$45.5MraisedMay 2017 · 18 investors · BiotechnologyRule 506(b)
▶$45.5MraisedMay 2017 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael RossDirector
- Carl GordonDirector
- Terrance McGuireDirector
- David MantusExecutive Officer
- Rene RussoExecutive Officer, Director
- Michael GrayExecutive Officer
- Dan BurgessDirector
- Eszter NagyExecutive Officer, Director
- Amy SchulmanDirector
- Tillman U. GerngrossExecutive Officer, Director
- Jan AdamsDirector
- Chris StevensExecutive Officer
- Claudio NessiDirector
- Offering amount
- $50.5M
- Amount sold
- $45.5M
- Proceeds to insiders
- $3M
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedApr 2016 · 10 investors · BiotechnologyRule 506(b)
▶$15MraisedApr 2016 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jan AdamsDirector
- Carl GordonDirector
- Amy SchulmanDirector
- Terrance McGuireDirector
- Claudio NessiDirector
- Daniel BurgessDirector
- Michael GrayExecutive Officer
- Eszter NagyExecutive Officer, Director
- Michael RossDirector
- Tillman GerngrossExecutive Officer, Director
- Rene RussoExecutive Officer
- Offering amount
- $15M
- Amount sold
- $15M
- Proceeds to insiders
- $770K
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedDec 2015 · 8 investors · BiotechnologyRule 506(b)
▶$4MraisedDec 2015 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Claudio NessiDirector
- Amy SchulmanDirector
- Michael RossDirector
- Carl GordonDirector
- Terrance McGuireDirector
- Tillman U GerngrossExecutive Officer, Director
- Dan BurgessDirector
- Eszter NagyExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06b
▶$20MraisedJun 2015 · 8 investors · BiotechnologyRule 506(b)
▶$20MraisedJun 2015 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carl GordonDirector
- Michael RossDirector
- Tillman U GerngrossExecutive Officer, Director
- Dan BurgessDirector
- Claudio NessiDirector
- Terrance McGuireDirector
- Michael RossDirector
- Eszter NagyExecutive Officer, Director
- Amy SchulmanDirector
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Jul 2013
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are X4 Pharmaceuticals's investors?
- X4 Pharmaceuticals's investors include Omega Funds, Polaris Partners.
- How much funding has X4 Pharmaceuticals raised?
- X4 Pharmaceuticals has disclosed $310.3M raised across 8 rounds.
- Where is X4 Pharmaceuticals headquartered?
- X4 Pharmaceuticals is headquartered in Boston, US.